Represents the information of accrued liability as per agreement.

No definition available.

Name:	eprs_AccruedLiability
Namespace Prefix:	eprs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable,

+ References

No definition available.

+ Details

Name:	eprs_AccruedRoyaltyObligations
Namespace Prefix:	eprs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable.

+ References

No definition available.

+ Details

Name:	eprs_AccruedRoyaltySettlement
Namespace Prefix:	eprs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Period the agreement may be automatically renewed, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsAutomaticRenewalPeriodOfAgreement
Namespace Prefix:	eprs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of billings to counterparty under terms of collaborative arrangement.

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsBillingsToCounterparty
Namespace Prefix:	eprs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Maximum number of additional compounds subject to exclusive, royalty-bearing licenses under agreement.

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsMaximumAdditionalCompoundsSubjectToExclusiveRoyaltyBearingLicenses
Namespace Prefix:	eprs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the maximum amount of payments to be received for the achievement of certain development and regulatory approval milestones.

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsMaximumPaymentsToBeReceivedForAchievementOfCertainDevelopmentAndRegulatoryApprovalMilestones
Namespace Prefix:	eprs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the maximum amount of payments to be received for the achievement of certain sales milestones.

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsMaximumPaymentsToBeReceivedForAchievementOfCertainSalesMilestones
Namespace Prefix:	eprs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the number of automatic renewals.

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsNumberOfAutomaticRenewals
Namespace Prefix:	eprs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the number of payment installments to terminate obligations under agreement.

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsNumberOfPaymentInstallmentsToTerminateObligationsUnderAgreement
Namespace Prefix:	eprs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of payments to be received for the achievement of specified regulatory milestones.

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsPaymentsToBeReceivedForAchievementOfSpecifiedRegulatoryMilestones
Namespace Prefix:	eprs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of payment to be made to terminate payment obligations under agreement.

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsPaymentToTerminateObligationsUnderAgreement
Namespace Prefix:	eprs_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

aaa

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsProceedsReceivableFromBillingsToCounterparty
Namespace Prefix:	eprs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of proceeds received from billings to counterparty under collaborative arrangement.

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsProceedsReceivedFromBillingsToCounterparty
Namespace Prefix:	eprs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Period the agreement is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsTermOfAgreement
Namespace Prefix:	eprs_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of upfront payments received under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	eprs_CollaborativeArrangementsUpfrontPaymentReceived
Namespace Prefix:	eprs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the amount of damages payable on breach of license agreement.

+ References

No definition available.

+ Details

Name:	eprs_DamagesOnBreachOfLicenseAgreement
Namespace Prefix:	eprs_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of units of accounting for recognition of revenue of deliverables.

+ References

No definition available.

+ Details

Name:	eprs_RevenueRecognitionNumberOfUnitsOfAccountingForDeliverables
Namespace Prefix:	eprs_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 13

-Section A

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 605

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SAB TOPIC 13.A.4(a).Q1 Response)

-URI http://asc.fasb.org/extlink&oid=27012821&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 323

-SubTopic 10

-Section 50

-Paragraph 3

-Subparagraph (a)(1)

-URI http://asc.fasb.org/extlink&oid=6382943&loc=d3e33918-111571

+ Details

Name:	us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix:	us-gaap_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 45

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 350

-SubTopic 30

-Section 50

-Paragraph 2

-Subparagraph ((a)(1),(b))

-URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275

+ Details

Name:	us-gaap_IntangibleAssetsNetExcludingGoodwill
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 03

-Paragraph 1

-Article 5

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 225

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SX 210.5-03.1(d),(e))

-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=eprs_Moksha8PharmaceuticalsIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=eprs_RanbaxyLaboratoriesLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=eprs_BOW015Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=eprs_ExclusiveLicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=eprs_OrygenHeadsOfAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=eprs_RoyaltyBearingAndNonTransferableLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=eprs_SupplyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Business Agreements (Details) (USD $) In Thousands, unless otherwise specified	12 Months Ended	1 Months Ended
	Dec. 31, 2014	Sep. 30, 2014 item	Nov. 30, 2014	Mar. 31, 2014	Jan. 31, 2014	Sep. 30, 2013	Dec. 31, 2013	Oct. 31, 2014
Business Agreements
Intangible asset	$ 5,500						$ 2,437
BOW015
Business Agreements
Upfront payment received	250
Ranbaxy Laboratories Limited [Member]
Business Agreements
Damages payable to Ranbaxy on breach of license agreement	500
Moksha8 Pharmaceuticals Inc
Business Agreements
Ownership percentage	17.00%
Moksha8 Pharmaceuticals Inc \| BOW015
Business Agreements
Payment to terminate payment obligations under agreement		1,500						1,400
Number of payment installments to terminate obligations under agreement		2
Accrued royalty settlement		1,500
Accrued royalty obligations								150
Accrued liability								1,400
Intangible asset		1,250						1,250
Royalty Bearing And Non Transferable License Agreement [Member] \| BOW015
Business Agreements
Number of units of accounting for recognition of revenue of deliverables	1
Royalty Bearing And Non Transferable License Agreement [Member] \| Ranbaxy Laboratories Limited [Member] \| BOW015
Business Agreements
Upfront payment received					500
Maximum payments to be received for achievement of certain development and regulatory approval milestones					1,000
Maximum payments to be received for achievement of certain sales milestones					10,000
Billings to Ranbaxy	1,250	125	250	250	125
Deferred revenue over the remaining term of license agreement			500
Proceeds received from Ranbaxy	1,000
Amount due from Ranbaxy	250
Orygen Heads Of Agreement [Member] \| Orygen Biotechnology [Member] \| BOW015
Business Agreements
Upfront payment received						250
Supply Agreement [Member] \| Ranbaxy Laboratories Limited [Member] \| BOW015
Business Agreements
Term of agreement		10 years
Number of automatic renewals		5
Automatic renewal period		2 years
Exclusive License And Collaboration Agreement [Member] \| Ranbaxy Laboratories Limited [Member] \| BOW015
Business Agreements
Maximum additional compounds subject to exclusive, royalty-bearing licenses	4
Exclusive License And Collaboration Agreement [Member] \| Livzon Mabpharm Inc
Business Agreements
Revenue recognized from licensing agreement	2,500
Term of agreement	20 years	20 years
Payments to be received for achievement of specified regulatory milestones		$ 2,500